blue cross blue shield glp-1 of Massachusetts will stop covering popular weight-loss drugs like Ozempic and Wegovy starting January 1, 2026. The decision comes as the costs for these medications have Blue Cross Blue Shield of
Description
Among 81,617 patients with existing substance-use disorders, the odds of related emergency department visits during the next three years were 31% lower for those on GLP-1s

Vedtofte L, Bahne E, Foghsgaard S, Bagger JI, Andreasen C, Strandberg C, et al

American journal of lifestyle medicine , 15598276251344827

New study provides answer As the popularity of drugs used for weight loss continues to explode, a new study is shedding light on which drug is most effective for weight loss

It highlights the ability of peripheral liraglutide to cross the BBB and specifically target hypothalamic ARC cells, eliciting significant appetite suppression and subsequent weight loss

Effects of liraglutide on body composition in people living with obesity or overweight: A systematic review
